Chinese medicine law implementation soon, anti-tumor proprietary Chinese medicine will be a big outbreak

2017-06-14 17:12:19 Source: Information Times

      July 1, July 1, "Chinese Medicine Law" is about to implement the implementation of the current proprietary Chinese medicine industry by the industry attention, especially anti-tumor proprietary Chinese medicine, some enterprises will be as a key product layout. Experts have said that in the domestic cancer treatment trend "Chinese and Western" background, anti-tumor proprietary Chinese medicine can play a larger space. However, since most of the anti-tumor proprietary Chinese medicine lacks effective clinical data, it is still difficult to break out in chemical and biological agents.

      Market: Many companies launched anti-tumor proprietary Chinese medicines

Antitumor drugs have been a number of pharmaceutical companies to dig the "gold mine." For the domestic market, according to McKinsey published in 2015, "China Hospital Drug Use Observation" report shows that the domestic hospital channel antitumor drug market since 2012 to 2014 since the compound annual growth rate of 17% in 2014 sales The amount of about 46 billion yuan, this strong growth in the future will continue.

      According to the classification of CMH, the current domestic market anti-tumor drugs mainly include anti-metabolic, proprietary Chinese medicines, hormones, monoclonal antibodies and protein kinase inhibitors, etc., of which anti-tumor proprietary Chinese medicine is "leader".

      In recent years, a number of domestic pharmaceutical companies focus on the layout of anti-tumor drugs, such as Yiling medicine Yangzheng Xiaoshi capsules, step-long pharmaceutical Yangzheng Mi, Tianshi Pharmaceutical, Hongzhi Pharmaceutical anti-cancer flat pills (acquisition of Hainan Dragon After the Church of the product) and Zhejiang Kanglaite Pharmaceutical Kanglaite injection (Chinese medicine Coix Seed extract), are pharmaceutical companies focus on creating varieties, in the market occupy a considerable share.

      This year, in the "Chinese Medicine Law" is about to implement the favorable background, some pharmaceutical companies launched a new anti-tumor proprietary Chinese medicine, also want to share in the market.

      For example, Guangzhou Baiyun Mountain in a medicine (hereinafter referred to as a medicine) on May 12 announced that the treatment of breast cancer, liver cancer and other malignant tumors of proprietary Chinese medicine "West Huang Wan" officially put on the market. Although the State Food and Drug Administration data show that the West Huang Wan currently has 64 production approval, but in a medicine on this "traditional Chinese medicine anti-cancer first medicine," the future prospects are high, according to the company's marketing department responsible person said , The product is expected to reach 100 million yuan after the listing of sales.

      Analysis: "Chinese and Western combination" of proprietary Chinese medicine or promising

      According to the National People's Social Department on February 21 this year, published "2017 basic medical insurance directory" shows that the use of cancer for a total of 44 kinds of drugs (Class A 3, B class 41), of which 22 kinds of anti-cancer drugs, Treatment of 22 kinds of drugs; compared with the 119 kinds of Western medicine still have a certain gap.

      From the status of cancer treatment, drugs, radiation therapy and surgery is the three major means of treatment, natural plant extracts, chemicals and monoclonal antibody targeting drugs are more widely used anti-tumor drugs, no matter what kind of treatment , Proprietary Chinese medicines are in the "adjuvant therapy" status.

In the expert view, in the domestic tumor treatment of Western medicine combined with the background, anti-tumor proprietary Chinese medicine can play a lot of space in the future. Chinese Academy of Engineering Tang Zhaoyou recently accepted the information Times reporter said that cancer treatment in the study of the West must also be combined with national conditions, anti-cancer and cancer control should be eliminated and transformation of the combination of Chinese and Western methods.

"Although there are many improvements in medicine, equipment and methods, drugs, radiotherapy and surgery, but unfortunately, these treatments are used to eliminate the strategy, while killing cancer, but also bring side effects. The transformation of the body, mainly to improve the body resistance, in order to more effectively play their own power to deal with residual cancer; the second is the transformation of residual cancer, so that reform.

      Tang Zhaoyou pointed out that Western medicine focus on micro and local, Chinese medicine focus on macro and overall, if the combination of the two will be "promising", especially in proprietary Chinese medicine research. At present, many studies have confirmed that Chinese medicine treatment for "anti-inflammatory" does have some effect, for example, in Japan had research confirmed that Xiaochu Hu Tang can reduce the inflammatory response.

      Primary hospital or into a new channel of anti-tumor proprietary Chinese medicines

It is understood that the main channel for the treatment of cancer drugs for the hospital. Industry insiders said that the current channel in the hospital, anti-tumor proprietary Chinese medicine is more in the hospital channels to compete, which means that anti-tumor proprietary Chinese medicine can "on the amount" to see whether the drug can enter the health insurance, the hospital opened The amount of big, there is no other open up new sales channels.

      Some products by virtue of its exclusive inclusion in the health insurance directory, such as Yiling Pharmaceutical antineoplastic drug main varieties - Yangzheng Xiaoshi Capsule, which is currently 2017 basic medical insurance directory of Class B anti-tumor drugs - the company 2016 Annual report shows that last year the drug has entered a provincial and municipal pharmacopoeia directory and a provincial capital of the new rural cooperative medicine directory, and "in clinical" application is more extensive.

      It is understood that the drug in the West Huang Wan is another way, after its listing with the major pharmacy cooperation, through the DTP pharmacy (that is, consumers prescription hospital to buy drugs) to promote the product. In the "Chinese Medicine Law" after the implementation of the Chinese medicine practitioners will open the form of the form of the record, the future "blossom" Chinese medicine clinic may be anti-tumor proprietary Chinese medicine "on the amount of" an important channel.

      Recently, the head of a pharmaceutical marketing department told reporters that in the "Chinese medicine law" and grading clinics and other new government good, anti-tumor sales of proprietary Chinese medicines will grow. First, the county hospital must set up cancer specialist, a large number of surgical treatment is not suitable for advanced cancer to stay in the grassroots to accept conservative treatment; Second, with the classification of diagnosis and treatment carried out, a certain amount of postoperative cancer patients need to turn under the grass-roots treatment; Is part of the provinces and cities have clear the poor population "9 kinds of serious disease grassroots treatment", which "esophageal cancer, gastric cancer, colorectal cancer," is the need to treat the project. "The future, the grassroots will likely become a new channel for the growth of anti-tumor proprietary Chinese medicine." The person in charge.

      Lack of clinical data, "auxiliary medication" status difficult to change

      Recently, Beijing Ding Chen medical consulting center Shi Lichen interview with reporters, said that no matter how many new channels of future drug sales, anti-tumor proprietary Chinese medicine "on the amount" is still difficult to reverse the "auxiliary medication" embarrassing position.

      "In the hospital channels in the circulation of chemical drugs, natural medicine or monoclonal antibody drugs, have a clear clinical data and indications of adaptation, the doctor opened the drug to understand the drug is more clear, but the proprietary Chinese medicine, most of the The product does not have clinical data and the exact therapeutic effect, the efficacy and risk of the drug is unknown, so the doctor in the treatment program, the anti-tumor proprietary Chinese medicine is open to open, even if the amount is far less than the current tumor Treatment medicine. "Shi Lichen said.